This Just In: The Fox Focus on Parkinson's

From the frontlines of Parkinson’s disease (PD) research, The Michael J. Fox Foundation’s (MJFF) 2020 Spring/Summer newsletter, The Fox Focus on Parkinson’s, is here. Add it to your stay-at-home reading list and learn how today, nearly 50,000 people — with and without Parkinson’s disease — are moving research forward from the comfort of their own households by providing their lived experience of PD in Fox Insight, our online long-term clinical study. Download the entire newsletter for stories like this and more, including: From the Desk of Todd Sherer, PhD — MJFF’s Chief Executive Officer discusses the Foundation’s response to COVID-19 and our commitment to the entire Parkinson’s community during this temporary, extraordinary circumstance. With Foundation Support, New Drugs Are Moving Closer to Market — Two new options offering relief from “off” times, including Ongentys (opicapone) and MJFF-funded Kynmobi (sublingual apomorphine), received U.S. Food and Drug Administration approval in April and May 2020, respectively, and more are on the way. To Live Well with Parkinson’s, “Ask the MD” — MJFF's Vice President of Medical Communications, Rachel Dolhun, MD, translates recent Parkinson’s research and related topics into articles, videos and downloadable guides. At MJFF, we continue to work with urgency and determination, and, as detailed in this edition, progress continues. Thank you for joining us in our urgent pursuit of the cure.